OREXQ
OREXIGEN THERAPEUTICS, INC COM
OREXIGEN THERAPEUTICS, INC COM historical holders
total: 1
Baupost Group OREXIGEN THERAPEUTICS, INC COM transactions over time
- Total transactions:
- 5
- New positions:
- 1
- Sold out:
- 1
- Added:
- 2
- Reduced:
- 1
- Held since:
- 2015 Q3
- Held for:
- 11 quarters
- Latest activity:
- 2018 Q2
Seth Klarman has been an institutional investor in OREXIGEN THERAPEUTICS, INC COM (OREXQ) since 2015 Q3. According to 2026 Q1 report, Seth Klarman doesn't hold any shares. The fund/company first acquired OREXQ in 2015 Q3, initially purchasing 821,363 shares. Since the initial investment, Baupost Group has made 4 more transactions in this position.
When did Seth Klarman exit their OREXQ position?
Seth Klarman no longer holds OREXIGEN THERAPEUTICS, INC COM (OREXQ). They sold off their entire position in 2018 Q2, closing out an investment that began in 2015 Q3.
When did Seth Klarman first invest in OREXQ?
Seth Klarman first invested in OREXIGEN THERAPEUTICS, INC COM (OREXQ) in 2015 Q3 at the reported quarter-end price of $1.86 per share, acquiring 821,363 shares in their initial purchase.
What is Seth Klarman's average cost basis for OREXQ?
Based on historical transaction data, Seth Klarman's estimated cost basis for OREXIGEN THERAPEUTICS, INC COM (OREXQ) is approximately $0.69 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $0.69
- Weighted AVG sell price:
- $3.01
OREXQ transactions history by Baupost Group
5 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2018 Q2
|
0.00%
|
$0.21
|
-100% (-2,226,839)
|
|||
|
2016 Q3
|
0.11%
|
$3.32
|
-90.00% (-20,041,560)
|
|||
|
2016 Q1
|
0.18%
|
$0.56
|
+881.68% (+20,000,000)
|
|||
|
2015 Q4
|
0.07%
|
$1.72
|
+176.17% (+1,447,036)
|
|||
|
2015 Q3
|
0.03%
|
$1.86
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.